New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2013
13:25 EDTACAD, ACAD, CYTK, CYTK, GILD, GILD, SHPG, SHPG, SNY, SNY, ACOR, ACOR, ALXN, ALXN, FURX, FURX, THLD, THLDCowen to host a conference
33rd Annual Health Care Conference is being held in Boston on March 4-6 with webcasted company presentations to begin on March 4 at 1:30 pm; not all company presentations may be webcasted. Webcast Link
News For ACAD;CYTK;GILD;SHPG;SNY;ACOR;ALXN;FURX;THLD From The Last 14 Days
Check below for free stories on ACAD;CYTK;GILD;SHPG;SNY;ACOR;ALXN;FURX;THLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2014
09:08 EDTCYTKCytokinetics volatility elevated into trial data announcement
Subscribe for More Information
07:35 EDTACADNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
April 7, 2014
17:02 EDTCYTKSAC Capital reports 5.5% passive stake in Cytokinetics
11:37 EDTCYTKOptions with increasing implied volatility: CYTK NSR NOW ETFC LF
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
09:01 EDTSHPGGenocea names Jonathan Poole as CFO
Subscribe for More Information
08:31 EDTGILDGilead announecs FDA priority review designation for Ledipasvir/Sofosbuvir
Gilead Sciences announced that the U.S. Food and Drug Administration has granted priority review to the company’s New Drug Application for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead filed the NDA for LDV/SOF on February 10, and the FDA has set a target action date under the Prescription Drug User Fee Act of October 10. The FDA has also assigned LDV/SOF a Breakthrough Therapy designation.
06:15 EDTTHLDThreshold Pharmaceuticals files $150M mixed securities shelf
Subscribe for More Information
05:28 EDTSNYGenzyme to resubmit Lemtrada application for FDA review
Subscribe for More Information
April 4, 2014
11:16 EDTCYTKOptions with decreasing implied volatility: MNKD GALT CYTK DLLR APOL
09:36 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA MU GNK AMZN FB GILD MA NFLX
April 3, 2014
11:24 EDTCYTKOptions with decreasing implied volatility: MNKD GALT CYTK DLLR
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
07:05 EDTTHLDThreshold to present results of 2 preclinical studies for combinations of TH-302
Subscribe for More Information
06:36 EDTSNYSanofi on lookout for acquisitions, expects growth in Africa, Reuters says
Subscribe for More Information
April 2, 2014
16:32 EDTGILDGilead Phase 3 sofosbuvir study meets primary efficacy endpoint
Gilead Sciences announced topline results from a Phase 3 clinical trial in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus infection. The study met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response rate. In the study, 97% of genotype 2 HCV-infected patients receiving 12 weeks of an all-oral regimen of sofosbuvir plus RBV achieved a sustained virologic response 12 weeks after completing therapy. Based on these trial results, Gilead anticipates submitting a New Drug Application for sofosbuvir to the Japanese Pharmaceutical and Medical Devices Agency by mid-2014
14:55 EDTACADACADIA management to meet with Piper Jaffray
Subscribe for More Information
10:43 EDTCYTKOptions with decreasing implied volatility: GALT CYTK EXAS CONN RH
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
06:21 EDTGILDGilead shares attractive at current levels, says Citigroup
Citigroup views shares of Gilead as "cheap" at current levels and keeps a Buy rating on the name with a $96 price target. Citi expects Gilead to generate $117B in free cash flow over the next 10 years and have $100B by 2023.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use